The regulatory nod applies to givastomig when administered alongside nivolumab and standard chemotherapy. This regimen targets previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas, specifically in patients whose tumors test positive for both Claudin 18.2 and PD-L1 markers.

NovaBridge officials pointed to phase 1b trial data as the catalyst for the designation, citing compelling efficacy and patient tolerability. By streamlining the development and review process, the FDA's fast track status aims to expedite access to new treatments for serious conditions where current medical options remain inadequate.